These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 32380416)
21. Rationally designed nanoparticle delivery of Cas9 ribonucleoprotein for effective gene editing. Chae SY; Jeong E; Kang S; Yim Y; Kim JS; Min DH J Control Release; 2022 May; 345():108-119. PubMed ID: 35247491 [TBL] [Abstract][Full Text] [Related]
22. CRISPR/Cas9-mediated gene knockout is insensitive to target copy number but is dependent on guide RNA potency and Cas9/sgRNA threshold expression level. Yuen G; Khan FJ; Gao S; Stommel JM; Batchelor E; Wu X; Luo J Nucleic Acids Res; 2017 Nov; 45(20):12039-12053. PubMed ID: 29036671 [TBL] [Abstract][Full Text] [Related]
23. Development of ionizable lipid nanoparticles and a lyophilized formulation for potent CRISPR-Cas9 delivery and genome editing. Sun Q; Zhang H; Ding F; Gao X; Zhu Z; Yang C Int J Pharm; 2024 Mar; 652():123845. PubMed ID: 38266942 [TBL] [Abstract][Full Text] [Related]
24. Special Focus Issue Part II: Recruitment of solid lipid nanoparticles for the delivery of CRISPR/Cas9: primary evaluation of anticancer gene editing. Akbaba H; Erel-Akbaba G; Senturk S Nanomedicine (Lond); 2021 May; 16(12):963-978. PubMed ID: 33970666 [No Abstract] [Full Text] [Related]
25. Dual-sgRNA CRISPR/Cas9 knockout of PD-L1 in human U87 glioblastoma tumor cells inhibits proliferation, invasion, and tumor-associated macrophage polarization. Fierro J; DiPasquale J; Perez J; Chin B; Chokpapone Y; Tran AM; Holden A; Factoriza C; Sivagnanakumar N; Aguilar R; Mazal S; Lopez M; Dou H Sci Rep; 2022 Feb; 12(1):2417. PubMed ID: 35165339 [TBL] [Abstract][Full Text] [Related]
27. Optimized CRISPR/Cas9 system for gene knockout in chicken DF1 cells. Zou K; Wang F; Zhang Z; Zhou Y; Li P; Wang D; Zhu M; Jia C; Wei Z Poult Sci; 2023 Oct; 102(10):102970. PubMed ID: 37562129 [TBL] [Abstract][Full Text] [Related]
28. CRISPR/Cas9-mediated 2-sgRNA cleavage facilitates pseudorabies virus editing. Tang YD; Guo JC; Wang TY; Zhao K; Liu JT; Gao JC; Tian ZJ; An TQ; Cai XH FASEB J; 2018 Aug; 32(8):4293-4301. PubMed ID: 29509513 [TBL] [Abstract][Full Text] [Related]
29. CRISPR-Cas9 Delivery by Artificial Virus (RRPHC). Yang S; Wu Q; Wei Y; Gong C Methods Mol Biol; 2019; 1961():81-91. PubMed ID: 30912041 [TBL] [Abstract][Full Text] [Related]
30. Development of poly(β-amino ester)-based biodegradable nanoparticles for nonviral delivery of minicircle DNA. Keeney M; Ong SG; Padilla A; Yao Z; Goodman S; Wu JC; Yang F ACS Nano; 2013 Aug; 7(8):7241-50. PubMed ID: 23837668 [TBL] [Abstract][Full Text] [Related]
31. Dual Supramolecular Nanoparticle Vectors Enable CRISPR/Cas9-Mediated Knockin of Retinoschisin 1 Gene-A Potential Nonviral Therapeutic Solution for X-Linked Juvenile Retinoschisis. Chou SJ; Yang P; Ban Q; Yang YP; Wang ML; Chien CS; Chen SJ; Sun N; Zhu Y; Liu H; Hui W; Lin TC; Wang F; Zhang RY; Nguyen VQ; Liu W; Chen M; Jonas SJ; Weiss PS; Tseng HR; Chiou SH Adv Sci (Weinh); 2020 May; 7(10):1903432. PubMed ID: 32440478 [TBL] [Abstract][Full Text] [Related]
32. Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications. Liu C; Zhang L; Liu H; Cheng K J Control Release; 2017 Nov; 266():17-26. PubMed ID: 28911805 [TBL] [Abstract][Full Text] [Related]
33. CRISPR-delivery particles targeting nuclear receptor-interacting protein 1 ( Shen Y; Cohen JL; Nicoloro SM; Kelly M; Yenilmez B; Henriques F; Tsagkaraki E; Edwards YJK; Hu X; Friedline RH; Kim JK; Czech MP J Biol Chem; 2018 Nov; 293(44):17291-17305. PubMed ID: 30190322 [TBL] [Abstract][Full Text] [Related]
34. Strategies for nonviral nanoparticle-based delivery of CRISPR/Cas9 therapeutics. Chen F; Alphonse M; Liu Q Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 May; 12(3):e1609. PubMed ID: 31797562 [TBL] [Abstract][Full Text] [Related]
35. Minimal 2'-O-methyl phosphorothioate linkage modification pattern of synthetic guide RNAs for increased stability and efficient CRISPR-Cas9 gene editing avoiding cellular toxicity. Basila M; Kelley ML; Smith AVB PLoS One; 2017; 12(11):e0188593. PubMed ID: 29176845 [TBL] [Abstract][Full Text] [Related]
36. Disabling Cas9 by an anti-CRISPR DNA mimic. Shin J; Jiang F; Liu JJ; Bray NL; Rauch BJ; Baik SH; Nogales E; Bondy-Denomy J; Corn JE; Doudna JA Sci Adv; 2017 Jul; 3(7):e1701620. PubMed ID: 28706995 [TBL] [Abstract][Full Text] [Related]
37. Optimized paired-sgRNA/Cas9 cloning and expression cassette triggers high-efficiency multiplex genome editing in kiwifruit. Wang Z; Wang S; Li D; Zhang Q; Li L; Zhong C; Liu Y; Huang H Plant Biotechnol J; 2018 Aug; 16(8):1424-1433. PubMed ID: 29331077 [TBL] [Abstract][Full Text] [Related]
38. Genome Editing for Cancer Therapy: Delivery of Cas9 Protein/sgRNA Plasmid via a Gold Nanocluster/Lipid Core-Shell Nanocarrier. Wang P; Zhang L; Xie Y; Wang N; Tang R; Zheng W; Jiang X Adv Sci (Weinh); 2017 Nov; 4(11):1700175. PubMed ID: 29201613 [TBL] [Abstract][Full Text] [Related]
39. Fabrication and characterization of PLGA nanoparticles encapsulating large CRISPR-Cas9 plasmid. Jo A; Ringel-Scaia VM; McDaniel DK; Thomas CA; Zhang R; Riffle JS; Allen IC; Davis RM J Nanobiotechnology; 2020 Jan; 18(1):16. PubMed ID: 31959180 [TBL] [Abstract][Full Text] [Related]
40. Development of a CRISPR/Cas9 System for Methylococcus capsulatus Tapscott T; Guarnieri MT; Henard CA Appl Environ Microbiol; 2019 Jun; 85(11):. PubMed ID: 30926729 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]